Display Settings:

Format

Send to:

Choose Destination
    J Hematol Oncol. 2009 Apr 28;2:19.

    Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.

    Source

    Department of Hematology, Second Affiliated Hospital to Second Military Medical University, 415 Fengyang Rd, Shanghai 200003, PR China. yuanzg@163.com

    Abstract

    Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology and characterized by various clinical manifestations and multiple organ involvement. It has been reported in association with POEMS syndrome and can progress to Kaposi's sarcoma or malignant lymphoma. The disease runs a more aggressive course and a poor prognosis. Optimal therapies have not been well established up to now. We here reported a case of rare MCD complicated with multiple myeloma who received bortezomib and achieved very good remission. To our knowledge, this is the first report on MCD in the setting of multiple myeloma with good response to bortezomib.

    PMID:
    19400935
    [PubMed - indexed for MEDLINE]
    PMCID: PMC2686727
    Free PMC Article

    Images from this publication.See all images (3) Free text

    Figure 3
    Figure 1
    Figure 2

      Supplemental Content

      Click here to read Click here to read

      Chemical compound information

      See all (2)...

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk